HOVON 133 (TRIANGLE) (FL)

HOVON 133 (TRIANGLE) (FL)

Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a randomized European MCL Network trial (TRIANGLE)


Study treatments

Arm A: standard of care
Alternating 3 cycles R-CHOP / 3 cycles R-DHAP induction followed by ASCT. Rituximab maintenance may be added.
Arm A+I
Alternating 3 cycles R-CHOP + ibrutinib / 3 cycles R-DHAP induction followed by ASCT and 2 years ibrutinib maintenance. Rituximab maintenance may be added.
Arm I
Alternating 3 cycles of R-CHOP + ibrutinib / 3 cycles R-DHAP induction, followed by 2 years ibrutinib maintenance. Rituximab maintenance may be added.


Inclusion criteria


Exclusion criteria


Participating sites

Link